Published in Am J Med on March 30, 1984
Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis (1975) 4.36
Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect Immun (1996) 3.51
Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa. Infect Immun (1978) 3.15
Loss of virulence associated with absence of flagellum in an isogenic mutant of Pseudomonas aeruginosa in the burned-mouse model. Infect Immun (1982) 2.48
Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: extracellular protease and elastase as in vivo virulence factors. Can J Microbiol (1979) 2.30
Flagella of Salmonella typhimurium are a virulence factor in infected C57BL/6J mice. Infect Immun (1984) 2.15
Flagellar preparations from Pseudomonas aeruginosa: animal protection studies. Infect Immun (1982) 2.01
Infected surface wound: an experimental model and a method for the quantitation of bacteria in infected tissues. Appl Microbiol (1972) 1.89
Experimental studies on the pathogenesis of infections due to Pseudomonas aeruginosa: direct evidence for toxin production during Pseudomonas infection of burned skin tissues. J Infect Dis (1977) 1.84
Burn wounds: microbiology, local host defenses, and current therapy. CRC Crit Rev Clin Lab Sci (1973) 1.70
Flagellar preparations from Pseudomonas aeruginosa: isolation and characterization. Infect Immun (1982) 1.67
Experience with Candida infections in the burn patient. Arch Surg (1972) 1.38
Epidemiology of Pseudomonas aeruginosa in a burns hospital: surveillance by a combined typing system. Appl Microbiol (1972) 1.27
Growth of Pseudomonas aeruginosa in normal and burned skin extract: role of extracellular proteases. Infect Immun (1979) 1.26
Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity. Oncogene (1999) 1.20
Avirulence of a Pseudomonas aeruginosa algC mutant in a burned-mouse model of infection. Infect Immun (1995) 1.20
Control of surface wound infection: skin versus synthetic grafts. Appl Microbiol (1973) 1.19
Epidemiology of pseudomonas aeruginosa in a burn hospital: evaluation of serological, bacteriophage, and pyocin typing methods. Appl Microbiol (1972) 1.17
Effect of Antibiotic and Chemical Dips on the Microflora of Packaged Salad Mix. Appl Microbiol (1960) 1.17
The pathogenesis of infections owing to Pseudomonas aeruginosa using the burned mouse model: experimental studies from the Shriners Burns Institute, Cincinnati. Can J Microbiol (1985) 1.12
Experimental studies of the pathogenesis of infections owing to Pseudomonas aeruginosa: elastase, an IgG protease. Can J Microbiol (1984) 1.10
Secreted products of a nonmucoid Pseudomonas aeruginosa strain induce two modes of macrophage killing: external-ATP-dependent, P2Z-receptor-mediated necrosis and ATP-independent, caspase-mediated apoptosis. Microbiology (2000) 1.07
Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations. J Trauma (1986) 1.07
Increased susceptibility to lethal Candida infections in burned mice preinfected with Pseudomonas aeruginosa or pretreated with proteolytic enzymes. Infect Immun (1986) 1.05
Enhanced survival in burned mice treated with antiserum prepared against normal and burned skin. J Trauma (1971) 1.03
Modifications of a Candida albicans biotyping system. J Clin Microbiol (1989) 1.02
Cytotoxicity testing of topical antimicrobial agents on human keratinocytes and fibroblasts for cultured skin grafts. J Burn Care Rehabil (1995) 1.01
Effect of a synthetic dressing formed on a burn wound in rats: a comparison of allografts, collagen sheets, and polyhydroxyethylmethacrylate in the control of wound infection. Appl Microbiol (1974) 0.98
Effect of proteolytic activity on virulence of Candida albicans in burned mice. Infect Immun (1990) 0.96
Evaluation of candida precipitin and agglutinin tests for the diagnosis of systemic candidiasis in burn patients. J Clin Microbiol (1977) 0.95
Noncytotoxic combinations of topical antimicrobial agents for use with cultured skin substitutes. Antimicrob Agents Chemother (1995) 0.94
Speciation and amphotericin B sensitivity studies on blood isolates of Candida from burned patients. J Clin Pathol (1973) 0.93
Hypersensitivity to diphtheria toxin by mouse cells expressing both diphtheria toxin receptor and CD9 antigen. Proc Natl Acad Sci U S A (1993) 0.92
Experimental studies of the pathogenesis of Pseudomonas aeruginosa infection: evidence for the in-vivo production of a lethal toxin. J Med Microbiol (1978) 0.91
Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: effect of treatment with protease inhibitors. Rev Infect Dis (1984) 0.88
Attachment of an aminoglycoside, amikacin, to implantable collagen for local delivery in wounds. Antimicrob Agents Chemother (1993) 0.86
Characterization of Candida isolates from pediatric burn patients. J Clin Microbiol (1988) 0.86
Circulating levels of tumour necrosis factor, interleukin 6 and proteolytic activity in a murine model of burn and infection. Burns (1996) 0.85
Antigenic components of normal and burned mouse skin. Experientia (1970) 0.84
Then and now: studies using a burned mouse model reflect trends in burn research over the past 25 years. Burns (1999) 0.83
Biochemical examination of sera during systemic Candida infection in mice. Infect Immun (1978) 0.82
Selection of topical antimicrobial agents for cultured skin for burns by combined assessment of cellular cytotoxicity and antimicrobial activity. Plast Reconstr Surg (1993) 0.82
Comparative evaluation of the Candida agglutinin test, precipitin test, and germ tube dispersion test in the diagnosis of candidiasis. J Clin Microbiol (1976) 0.82
Components of the increased circulating proteolytic activity in pediatric burn patients. J Trauma (1992) 0.81
Experience with amphotericin-B in the treatment of systmeic candidiasis in burn patients. Am J Surg (1977) 0.81
Immunologic sequelae of thermal injury. I. Frequency and relationship of epithelial antibodies to extent of burn. Clin Immunol Immunopathol (1976) 0.81
Proteolytic activity and fatal gram-negative sepsis in burned mice: effect of exogenous proteinase inhibition. Infect Immun (1994) 0.80
Characterization and biological activity of the monocytosis-producing agent of Listeria monocytogenes. J Bacteriol (1969) 0.79
Effect of a human IgG preparation rich in antibodies to a wide range of lipopolysaccharides on gram-negative bacterial sepsis in burned mice. APMIS (1993) 0.79
Effect of challenge with Candida albicans strains with different levels of virulence on plasma proteins in burned mice. Infect Immun (1991) 0.78
Effective management of microbial contamination in cultured skin substitutes after grafting to athymic mice. Wound Repair Regen (2006) 0.78
Pseudomonas aeruginosa isolates with varying serotype and multiple antibiogram patterns from individual burn patients. J Burn Care Rehabil (1987) 0.78
Salmonella typhimurium virulence in a burned-mouse model. Infect Immun (1989) 0.78
Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns. Antibiot Chemother (1971) (1987) 0.78
The effect of a collagen dressing on contaminated surgical wounds in rats. Langenbecks Arch Chir (1976) 0.78
Antibody activity, contained in a commercial pseudomonas hyperimmune globulin product, against various members of the family Enterobacteriaceae. J Burn Care Rehabil (1988) 0.78
Antimicrobial resistance. Burns (1999) 0.77
Active immunisation of mice against muscle damage mediated by Candida albicans. J Med Microbiol (1979) 0.77
Delivery and activity of antimicrobial drugs released from human fibrin sealant. J Burn Care Rehabil (1994) 0.77
Effects of immunoglobulin G and low-dose amphotericin B on Candida albicans infections in burned mice. Antimicrob Agents Chemother (1992) 0.77
Causes of colonization of autografted burn wounds. J Burn Care Rehabil (1991) 0.76
In situ production of a synthetic barrier dressing for burn wounds in rats. Infect Immun (1975) 0.76
Effect in mice of injection of viable Candida albicans and a cell-free sonic extract on circulating platelets. Infect Immun (1973) 0.76
Letter: Candida isolates. J Clin Pathol (1974) 0.75
Eighteen months of routine topical antimicrobial susceptibility testing of isolates from burn patients: results and conclusions. J Antimicrob Chemother (1979) 0.75
Candida albicans growth studies: a hypothesis for the pathogenesis of Candida infections in burns. J Burn Care Rehabil (1992) 0.75
Effect of thermal injury on the adherence of Candida albicans to murine splenic tissue. Infect Immun (1997) 0.75
Incorrect comparison relating test MICs and clear zone diameter by use of NAWD. J Burn Care Rehabil (1998) 0.75
In vitro inactivation of silver sulphadiazine by the addition of cerium salts. Burns Incl Therm Inj (1982) 0.75
Immunologic sequelae of thermal injury. J Trauma (1981) 0.75
Para-chloro-meta-xylenol (PCMX): a new, potential topical antimicrobial agent. J Burn Care Rehabil (1987) 0.75
In vivo muscle damage during Candida infection. Sabouraudia (1980) 0.75
Basal cell layer antibodies in patients with burns. Arch Dermatol (1979) 0.75
In vitro susceptibility-resistance patterns of bacterial isolates from burn patients to augmentin and timentin. J Burn Care Rehabil (1987) 0.75
Candida parapsilosis fungemia in burn patients: report of three cases. Burns Incl Therm Inj (1984) 0.75
IgG and complement-fixing pseudointercellular antibodies after thermal injuries. Arch Dermatol (1974) 0.75
In-vitro susceptibility of organisms isolated from burns to topical co-trimoxazole. J Antimicrob Chemother (1981) 0.75
Gentamicin resistant Pseudomonas aeruginosa in a burns unit. J Antimicrob Chemother (1976) 0.75
Antibodies to basal cells. J Invest Dermatol (1981) 0.75
Enhancement of tissue damage by Candida albicans in cortisone or nitrogen mustard-treated mice. Can J Microbiol (1979) 0.75
Recombinant neutral endopeptidase decreases oedema in the skin of burned guinea-pigs. Burns (1996) 0.75
Immunologic sequelae of thermal injury autoantibodies in acute adult burn patients. Arch Dermatol Res (1982) 0.75
'Metabolic' factors in thermal injury: role of nucleic acids. Burns Incl Therm Inj (1983) 0.75